JYSELECA is a once-daily, oral JAK1 inhibitor1,2

JAK1-preferential inhibition

JYSELECA is a JAK1-preferential inhibitor with more than five-fold higher potency for JAK1 over other JAK isoforms, as measured in biochemical assays, the clinical relevance of which is uncertain1,2

Proinflammatory cytokine signalling via JAK1-containing protein complexes has been implicated in UC pathogenesis3,4

In human cellular assays, JYSELECA preferentially inhibited JAK1/JAK3-, JAK1/JAK2- and JAK1/TYK2-mediated signalling, with functional selectivity over cytokine receptors that signal via pairs of JAK2 or JAK2/TYK25

The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known

MoA, mode of action; JAK, Janus kinase; TYK, tyrosine kinase; UC, ulcerative colitis.

References: 1. Danese S, Argollo M, Le Berre C, et al. Gut 2019;68:1893–1899. 2. Salas A, Hernandez-Rocha C, Duijvestein M, et al. Nat Rev Gastroenterol Hepatol 2020;17:323–337. 3. Schwartz DM, Kanno Y, Villarino A, et al. Nat Rev Drug Discov 2017;17:78. 4. Virtanen AT, Haikarainen T, Raivola J, et al. BioDrugs 2019;33:15–32. 5. Galien R, Vayssiere B, de Vos S, et al. Arthritis Rheum 2013;65 Suppl 10:Abstract 478.

INDICATIONS: JYSELECA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

GB-UC-JY-202303-00004  | Date of preparation:  October 2023